Screener
Merck & Co. MRK Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 73%-3.6pp | 73.9%-2.5pp | 74.8%-1.5pp | 77.2%+1.4pp | 76.6%+1.3pp | |
| Net margin | 4.8%-21.0pp | 13.6%-13.7pp | 28.1%+1.4pp | 29.6%— | 25.8%— | |
| Returns | ||||||
| Return on equity | 7%-28.5pp | 19%-20.3pp | 36.9%-3.9pp | 39.5%— | 35.4%— | |
| Return on invested capital | 3.7%-18.0pp | 10.8%-12.8pp | 22.2%-1.9pp | 25.8%— | 21.8%— | |
| Efficiency | ||||||
| Asset turnover | 0.5×0.0× | 0.5×0.0× | 0.5×-0.1× | 0.5×0.0× | 0.6×0.0× | |
| Liquidity | ||||||
| Current ratio | 1.3×-0.1× | 1.3×-0.1× | 1.5×+0.2× | 1.7×+0.3× | 1.4×0.0× | |
| Leverage | ||||||
| Debt-to-equity | 1.4×+0.6× | 1.1×+0.3× | 1×+0.1× | 0.8×-0.1× | 0.8×-0.2× | |
| Net debt / EBITDA | 5.4×+4.1× | 3×+1.7× | 1.6×+0.3× | 1×— | 1.4×— | |
| Valuation | ||||||
| Market capitalization | $354.8B+58.7% | $297.4B+31.2% | $261.26B+3.8% | $209.64B-27.1% | $201.69B-35.7% | |
| Price / earnings | 111.8×+100× | 33.3×+20.3× | 14.3×-0.4× | 11×— | 12.3×— | |
| Price / sales | 5.3×+1.8× | 4.5×+1.0× | 4×+0.1× | 3.3×-1.3× | 3.2×-1.8× | |
| Price / book | 8.5×+4.1× | 6.5×+1.8× | 5×-0.5× | 4×-2.4× | 4.1×-3.1× | |
| EV / EBITDA | 44.2×+33.8× | 23.1×+11.7× | 12.4×-0.2× | 9.8×— | 10.8×— | |
| Dividend yield | 2.3%-1.3pp | 2.8%-0.7pp | 3.1%0.0pp | 3.9%+1.2pp | 4%+1.5pp |
FAQ
- Where do Merck & Co.'s ratios come from?
- Every ratio is computed from Merck & Co.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
